Facial Emotion Recognition in Patients With Euthymic Bipolar Disorder I and II

NCT ID: NCT05922956

Last Updated: 2025-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-01

Study Completion Date

2023-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The facial emotion recognition is a basic social skill for successful social interactions. Several meta-analyses and recent studies found impairments of the perception of facial emotions in patients with euthymic bipolar disorder. Few studies compared recognition of facial emotions impairments during euthymia in patients with bipolar disorder type 1 and 2. These studies included low population samples (N\<60). There were discrepancies in results of these studies. Szanto suggested that facial emotion recognition impairments were correlated with suicidal risk and social isolation. These impairments should be taking into account regarding psycho-social treatments in patients with bipolar disorder.

This study aims to evaluate facial emotion recognition in patients with bipolar I and II disorders compared to healthy controls, using the facial emotion recognition test (TREF). The objective of the present study is to compare TREF scores in a group of patients with bipolar 1, a group of patients with bipolar 2 disorder and a group with healthy controls. In addition, the investigators will investigate the relationships between TREF scores and levels of self-esteem and mental well-being.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Social Cognition Facial Emotion Recognition Facial Affect Bipolar Disorder I and II

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with bipolar disorder 1

Group Type EXPERIMENTAL

Facial emotion recognition test

Intervention Type OTHER

Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires

patients with bipolar disorder 2

Group Type EXPERIMENTAL

Facial emotion recognition test

Intervention Type OTHER

Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires

healthy controls

Group Type ACTIVE_COMPARATOR

Facial emotion recognition test

Intervention Type OTHER

Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Facial emotion recognition test

Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient group :
* Male or female patients, between 18 and 60 years old
* Diagnosis of Bipolar Disorder I or Bipolar Disorder II according to DSM-IV criteria, using the French version of the Mini-International Neuropsychiatric Interview (MINI)
* Strictly euthymic defined by Hamilton Depression Rating Scale (17 items) ≤ 5 and Young Mania Rating Scale ≤ 5 for at least two months.
* Native French speakers
* Affiliated to the French social security system
* Giving their written informed consent

Control group :

* Male or female control subjects, aged between 18 and 60 years old, assessed using TREF
* Native French speakers
* Giving their written informed consent

Exclusion Criteria

* Patient group :
* History of mental retardation assessed by the French version of the National Adult Reading Test
* Neurological illness or any clinical condition that could affect cognitive performance (history of head injury with loss of consciousness lasting more than 5 minutes multiple sclerosis, stroke etc.)
* Electroconvulsive therapy within the last 6 months
* Alcohol and Drug dependence (except tobacco and caffeine) according to DSM-IV criteria using the French version of the Mini-International Neuropsychiatric Interview (MINI).
* Learning disability or difficulty with fluent use of the French language
* Patient with mandatory care
* Long-Term use of non-psychotropic medication with psychotropic effects (opiates, Baclofen)

Control group :

* History of mental retardation estimated by the French version of the National Adult Reading Test
* Neurological illness or any clinical condition that could affect cognitive performance (history of head injury with loss of consciousness lasting more than 5 minutes multiple sclerosis, stroke etc.)
* Current Mood disorder/ Lifetime Psychotic Disorder according to DSM-IV criteria using the French version of the Mini-International Neuropsychiatric Interview (MINI)
* Neither history of psychotic or affective disorders in a first-degree family member
* Alcohol and Drug dependence (except tobacco and caffeine) according to DSM-IV criteria using the French version of the Mini-International Neuropsychiatric Interview (MINI)
* Learning disability or difficulty with fluent use of the French language
* Long-Term use of non-psychotropic drugs with psychotropic effects (opiates, Baclofen) and psychotropic drugs
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier le Vinatier

UNKNOWN

Sponsor Role collaborator

Pôle Ressource Évaluation et Réhabilitation Psycho-sociale, EPSM de l'Oise

UNKNOWN

Sponsor Role collaborator

Centre de santé mentale MGEN

UNKNOWN

Sponsor Role collaborator

Centre Hospitalier Philippe Pinel, Amiens

UNKNOWN

Sponsor Role collaborator

Centre Hospitalier Universitaire, Amiens

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Amiens

Amiens, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PI2020_843_0009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.